NCT05902247View on ClinicalTrials.gov

Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

December 29, 2025

Study Completion Date

December 29, 2025

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
RADIATION

Radionuclide Therapy

To evaluate the tolerability and safety of 225Ac-PSMA I\&T in patients with metastatic prostate cancer

Trial Locations (1)

3015GD

RECRUITING

Erasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

lead

Erasmus Medical Center

OTHER